Clinical Cancer Research CR Balducci Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Clinical Cancer Research 14, 347, January 15, 2008. doi: 10.1158/1078-0432.CCR-07-0493
© 2008 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prabhakar, B. S.
Right arrow Articles by Prasad, K. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prabhakar, B. S.
Right arrow Articles by Prasad, K. V.

Molecular Pathways

Role of IG20 Splice Variants in TRAIL Resistance

Bellur S. Prabhakar, Nirupama Mulherkar and Kanteti V. Prasad

Authors' Affiliation: Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, Illinois

Requests for reprints: Bellur S. Prabhakar, Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, 835 South Wolcott Street (MC 790), Chicago, IL 60612. Phone: 312-996-4945; Fax: 312-996-6415; E-mail: bprabhak{at}uic.edu.

Abstract

Tumor necrosis factor receptor–related apoptosis-inducing ligand (TRAIL) can induce apoptosis primarily in cancer cells with little or no effect on normal cells; therefore, it has the potential for use in cancer therapy. TRAIL binding to death receptors DR4 and DR5 triggers the death-inducing signal complex formation and activation of procaspase-8, which in turn activates caspase-3, leading to cell death. Like FasL, TRAIL can trigger type 1 (caspase-8 -> caspase-3) or type 2 (caspase-8 -> Bid cleavage -> capsase-9 -> caspase-3) apoptotic pathways depending on the cell type. Some cancers are resistant to TRAIL treatment because most molecules in the TRAIL signaling pathway, including FLIPs and IAPs, can contribute to resistance. In addition, we have identified an essential role for splice variants of the IG20 gene in TRAIL resistance.

Background

Given the role of tumor necrosis factor receprtor–related apoptosis-inducing ligand (TRAIL) in apoptosis and its expression on immune cells, it is likely to contribute significantly to immune surveillance of virus-infected and cancer cells. TRAIL has the ability to kill tumor cells, with little or no effect on most normal cells. Systemic administration of TRAIL can cause tumor shrinkage/elimination, without causing significant side effects (reviewed in ref. 1). TRAIL in combination with chemotherapy and UV radiation can be more effective. In contrast to FasL or tumor necrosis factor {alpha}–based treatments that are associated with fulminant hepatitis and systemic inflammation, respectively, TRAIL administration seems to lack these side effects; therefore, TRAIL is an attractive candidate for cancer therapy (1–6). TRAIL is expressed as a trimeric type II transmembrane protein on mainly natural killer and natural killer–T cells. TRAIL can bind to five distinct receptors—death receptor 4 (DR4 or TRAILR-1), death receptor 5 (DR5 or TRAILR-2), decoy receptor 1 (DcR1, TRAILR-3, LIT or TRID), decoy receptor 2 (DcR2, TRAILR-4, TRUNDD), and osteoprotegerin. Among these, only DR4 and DR5 contain death domains and are able to mediate the death signal. DcR1 and DcR2 engage TRAIL, but they fail to signal. Osteoprotegerin is a soluble receptor and its affinity for TRAIL is weak.

TRAIL-mediated apoptosis signaling in cancer cells is similar to that seen with Fas (CD95). DR4 and DR5, through their cytoplasmic death domains, bind to the FADD death domain, which in turn interacts with procaspase-8 (or caspase-10) through its death effector domain. TRAIL binding causes increased recruitment of proteins to this death-inducing signaling complex (DISC) leading to proximity-induced caspase-8 activation. This causes subsequent caspase-3 (or caspase-7) activation, resulting in degradation of inhibitor of caspase-activated DNase. Proteolysis of inhibitor of caspase-activated DNAase releases CAD that cleaves the genomic DNA (refs. 7, 8; Fig. 1 ).


Figure 1
View larger version (65K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Molecular mechanisms of resistance to TRAIL-induced apoptosis. The diagram shows the TRAIL-induced signaling, and the interplay between cell proliferation and death signals. Green lines, up-regulation; red lines, down-regulation. Thickness of lines indicates relative strengths of signals. The FLIPs, IAPs, and some of the Bcl2 family members are the major contributors to TRAIL resistance. The IG20 gene splice variants, MADD and DENN-SV, are constitutively expressed at high levels in all cancer cells and tissues tested to date and they confer resistance to TRAIL, especially in the absence of IG20pa. MADD can directly interact with death receptors (DR4 and DR5) and inhibit activation of endogenous caspase-8. MADD can also cause mitogen-activated protein kinase activation and is therefore an important early regulator of TRAIL-induced cell death. On the other hand, IG20pa, when expressed, can act like a dominant negative MADD and enhance DISC formation, and be part of it. DENN-SV when coexpressed with MADD can promote the prosurvival transcription factor NF-{kappa}B and promote cell proliferation. As shown above, the cell survival/proliferation and death pathways regulate each other through both protein-protein interactions and transcription. Perturbations in the above pathways could contribute to TRAIL resistance. Therefore, a combination of TRAIL treatment with targeted suppression of specific proteins that contribute to resistance is likely to be a more effective treatment against cancer.

 
In addition to the type 1 pathway, TRAIL-mediated apoptosis can also recruit the intrinsic or type 2 pathway under conditions in which the caspase-8 levels are limiting and the proapoptotic molecule Bid is expressed. The intrinsic cell death pathway is regulated through a variety of Bcl2 family members that act primarily in mitochondria and endoplasmic reticulum. The antiapoptotic members of the Bcl2 family, such as Bcl2, Bcl-xL, and Mcl1, contain four Bcl2 homology (BH1-BH4) domains, whereas proapoptotic members such as Bax and Bak lack BH4 domain. In healthy cells, Bcl2 and Bcl-xL neutralize the activity of Bax/Bak. The equilibrium between the antiapoptotic and proapoptotic Bcl2 family members is regulated by the mobilization of a third class of proapoptotic Bcl2 family members such as Bid, Bad, Puma, and Noxa. In a type 2 pathway, the activated caspase-8 cleaves Bid to form tBid whose BH3 domain is now exposed, allowing it to interact with Bcl2/Bcl-xL and trigger intrinsic cell death pathway (9, 10). A disruption in the equilibrium results in oligomerization of Bax/Bak at mitochondrial outer membrane, leading to loss of mitochondrial integrity and leakage of cytochrome c into cytosol. Cytochrome c then interacts with Apaf1 and procaspase-9 and facilitates oligomerization and activation of caspase-9 that results in caspase-3 activation (ref. 11; see Fig. 1).

Cellular FLICE Inhibitory Proteins in TRAIL Resistance

Apoptotic pathways are kept in check by cell proliferation and survival signaling. For instance, c-FLIP is an inhibitor of death receptor signaling as it competes with caspase-8 to bind to FADD (12). Structurally, c-FLIP closely resembles caspase-8 but lacks the caspase-8 enzymatic activity due to substitution of a key cysteine with aspartate in the active site. Some of the c-FLIP isoforms [e.g., c-FLIPL (p55), c-FLIPS (p26), c-FLIPR (p24), and p22] also activate the prosurvival transcription factor nuclear factor-{kappa}B (NF-{kappa}B). The p22 form can associate with NEMO, and be a part of the IKK complex causing NF-{kappa}B activation. In addition, c-FLIPL is an NF-{kappa}B–responsive gene and, on expression, it can inhibit Fas as well as TRAIL-induced apoptosis (refs. 12–16; Fig. 1). The death effector domain in the FLIPs competes with the DED of caspase-8 for binding to FADD in the DISC, thereby inhibiting caspase-8 activation. Compared with FLIPL, FLIPS that lacks even the inactive protease domain seems to be much more effective in caspase-8 inhibition.

Evidence for the altered expression of this pathway has been reported in multiple types of cancer. TRAIL-resistant endometrial carcinomas express relatively high levels of c-FLIP and its down-modulation using either actinomycin D or specific small interfering RNA renders the carcinoma highly sensitive to TRAIL killing. Herpes virus–induced Kaposi's sarcoma shows elevated levels of FLIP due to the production of V-FLIP. This can increase the basal levels of NF-{kappa}B activity, leading to enhanced expression of prosurvival genes that contribute to higher incidence of cancers. Elevated c-FLIP levels have been linked to TRAIL resistance in human melanomas; B-cell lymphomas; Reed-Steinberg's cells of Hodgkin's lymphoma; and carcinomas of the prostrate, the stomach, and the urinary bladder. Similarly, elevation in c-FLIP levels along with survivin is often observed in the highly fatal form of glioblastoma multiforme (17–27). A related member PED that targets caspase-8 and is highly expressed in B-cell chronic lymphocytic leukemia may confer TRAIL resistance (28). Specific NF-{kappa}B inhibitors can be administered to down-modulate not only c-FLIPs but also IAPs to sensitize TRAIL resistance carcinomas to TRAIL-mediated apoptosis (ref. 29; Fig. 2 ).


Figure 2
View larger version (74K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Potential targets for combinatorial therapy with TRAIL. Green, key molecules involved in the TRAIL-induced apoptosis; yellow, antiapoptotic factors that contribute to TRAIL resistance in various cancers. Purple, potential therapeutic agents that can synergize with TRAIL and enhance its therapeutic efficacy. Either pan abrogation of all IG20 isoforms or down-modulation of MADD alone can cause spontaneous apoptosis and/or enhance susceptibility to TRAIL treatment. Increased expression of the IG20pa isoform can also render cells more susceptible to TRAIL-induced apoptosis, perhaps by acting as a dominant negative form of MADD.

 
Inhibitors of Apoptosis in TRAIL Resistance

Inhibitors of apoptosis (IAP) proteins block apoptosis by binding either to effector caspase-3 and caspase-7 and/or to initiator caspase-9. They have one or three tandem baculoviral inhibitory repeat (BIR) domains. To date, six IAPs have been identified—cIAP1, cIAP2, X-IAP (X linked), NIAP (neuronal), Survivin, and BRUCE (Bir repeat containing ubiquitin conjugating enzyme), of which XIAP is the most potent. During intrinsic apoptosis, in addition to cytochrome c, Smac/Diablo is leaked into the cytoplasm wherein they interact with the BIR domains of IAPs and neutralize them. In type II cells, where caspase-8 activity is limiting, reduced or increased levels of Smac/Diablo or IAPs, respectively, can confer TRAIL resistance (reviewed in ref. 30). Many human cancers harbor high levels of IAPs and a majority of pancreatic carcinoma cell lines are TRAIL resistant due to poor release of Smac/Diablo from mitochondria (31, 32). Down-modulation of XIAP in NSCLC xenografts renders them highly susceptible to TRAIL treatment in mouse models (33–35). Although inhibition of IAPs with Smac peptides or with phenylurea may not be sufficient, it is very likely that in combination with TRAIL, it will significantly increase the efficacy of the treatment of cancers that are refractory to TRAIL treatment due to elevated levels of IAPs (refs. 36, 37; Fig. 2).

Bcl2 Family Members in TRAIL Resistance

The Bcl2 family members can contribute to TRAIL resistance that can be reversed with BH3 mimetic Nona peptides (38, 39). Surprisingly, in some prostate and colon cancer cells, TRAIL induces resistance through increased expression of the antiapoptotic protein Bcl-xL, presumably due to activation of NF-{kappa}B (40). Mcl-1, an antiapoptotic member of the Bcl2 family, is highly expressed in multiple myeloma, hepatocellular carcinoma, and liver metastasis of colorectal carcinoma (41, 42) and confers resistance to various therapies including TRAIL. In pancreatic ductal carcinoma cells, expression of Bcl-xL not only confers resistance to TRAIL but also unravels the ability of TRAIL to activate the NF-{kappa}B–mediated prosurvival pathway and enhance metastasis. This was elegantly shown by orthotopic transplantation of ductal carcinoma cells into severe combined immunodeficient mouse pancreas. Only three TRAIL treatments in these mice were enough to trigger metastasis of the pancreatic cancer to liver, spleen, and peritoneum without any apparent effect on the growth of the primary tumor (43). A similar observation has been described in another study using cholangiocarcinoma cells. TRAIL treatment promoted tumor cell migration, and silencing of NF-{kappa}B had no discernible effect. In these cells, the TRAIL resistance was found to be caused by Mcl-1 and, unlike Bcl-xL, it is not regulated by NF-{kappa}B (44, 45). Therefore, a careful evaluation of the molecular nature of cancer is necessary before embarking on TRAIL treatment for cancers. The BH3 mimetic ABT737, which is a potent inhibitor of both Bcl2 and Bcl-xL, and others are currently in clinical trials and by themselves seem to be highly effective. They may not, however, overcome the resistance offered by a related BCL2 family member Mcl1 as seen in Fig. 2 (44).

IG20 Isoforms and their Role in TRAIL-Induced Signaling

The IG20 splice variants play important roles in cell survival, proliferation, and apoptosis, and vesicular trafficking. The IG20 gene can encode at least four different splice variants, namely IG20pa, MADD/DENN, IG20-SV2, and DENN-SV (46–50). IG20 isoforms play significant roles in cancer cell proliferation, survival, and death (50–56). Most cancer cells constitutively express MADD and DENN-SV with varying levels to no expression of IG20pa and IG20-SV2 (50). Earlier studies, using antisense oligodeoxynucleotides, showed that knockdown of all IG20-SVs can result in spontaneous apoptosis of cancer cells but not normal cells in vitro as well as in vivo (55–57). Although an indispensable role for IG20 in cancer cell survival was shown, these studies failed to delineate the relative importance of different IG20-SVs.

In our recent studies using short hairpin RNAs that specifically target either exon 15, which is expressed in all isoforms of IG20 (Mid), or exons 13L or 16, which are differentially expressed in IG20-SVs, we were able to selectively knock down either all or combinations of IG20-SVs in HeLa and PA-1 cells to determine their role in cell survival. The ovarian carcinoma PA1 cells are resistant to TRAIL-induced apoptosis and express only MADD and DENN-SV, indicating that either or both of these isoforms are indispensable for cell survival and/or TRAIL resistance. Knockdown of MADD, and not DENN-SV, enhanced spontaneous as well as TRAIL-induced apoptosis through caspase-8 activation. Further, endogenous MADD could inhibit caspase-8 activation, at the DISC, by sequestering the DR4/DR5 through direct interactions. MADD per se does not interact with caspase-8 or FADD nor does it affect their interactions with death receptors. In contrast, overexpression of IG20pa rendered even PA1 cells highly susceptible to TRAIL through enhanced recruitment of DISC and activation of caspase-8. Knockdown of endogenous IG20pa has no discernible effect on spontaneous or TRAIL-induced apoptosis, however. Although loss of DENN-SV has no apparent effect on apoptosis, expression of DENN-SV can lead to increased resistance to TRAIL, most likely through enhanced production of prosurvival factors through NF-{kappa}B activation (refs. 50, 52–54, 58, 59,; Fig. 1).

Taken together, these studies show a prosurvival role for MADD, and expression of MADD especially in the absence of IG20pa seems to confer resistance to TRAIL-induced apoptosis. IG20pa, when expressed, behaves like a dominant negative MADD. It is therefore very likely that the constitutively expressed isoforms, MADD and DENN-SV, contribute to TRAIL resistance by inhibiting caspase-8 and activating NF-{kappa}B, respectively. Our results clearly show that knockdown of all IG20 splice variants or the MADD variant using a lentiviral vector that can express either mid or 13L small interfering RNA, respectively, not only induces significant apoptosis but also synergizes with TRAIL treatment (Fig. 2).

Clinical-Translational Advances

TRAIL seems to be an excellent choice of treatment for a variety of cancers. There is a distinct possibility, however, that the treatment itself can quickly induce resistance and promote metastasis through activation of NF-{kappa}B. In addition, intrinsic TRAIL resistance seems to occur more frequently than what was originally anticipated, and the signaling components in the TRAIL-mediated cell death pathway, such as FLIP and IAP, seem to play a significant role. Loss-of-function mutations in TRAIL receptors, overexpression of decoy receptors, and loss of caspase-8 expression due to gene methylation can also contribute to TRAIL resistance (60–67). Our recent studies with various splice variants of IG20 unraveled yet another level of regulation of TRAIL-induced cell death. Constitutive expression of the MADD and DENN-SV isoforms, especially in the absence of IG20pa and IG20--SV2, seems to confer TRAIL resistance. As shown in the figure, MADD seems to regulate the very proximal event in TRAIL signaling. It is possible that MADD can sequester DR4/DR5 receptors and thus negatively regulate TRAIL-induced apoptosis in addition to its inhibitory effect on endogenous caspase-8 activation at the DISC. Therefore, to maximize the efficacy of TRAIL, it is critical that we rapidly and reliably identify the potential TRAIL resistance mediators. A combinatorial approach that will target the key contributors to TRAIL resistance and includes TRAIL is likely to be a more effective therapeutic approach to cure cancer. A single combination is unlikely to be the cure all and thus a cancer-specific combinatorial therapy based on the molecular expression pattern of TRAIL resistance markers might be more effective (Fig. 2).

Footnotes

Grant support: NIH grant 5R01CA107506.

Received 2/28/07; revised 4/13/07; accepted 4/27/07.

References

  1. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66–75.[CrossRef][Medline]
  2. Belka C, Schmid B, Marini P, et al. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene 2001;20:2190–6.[CrossRef][Medline]
  3. Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A 2000;97:1754–9.[Abstract/Free Full Text]
  4. Arizono Y, Yoshikawa H, Naganuma H, Hamada Y, Nakajima Y, Tasaka K. A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents. Br J Cancer 2003;88:298–306.[CrossRef][Medline]
  5. Hymowitz SG, Christinger HW, Fuh G, et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 2001;4:563–71.[CrossRef]
  6. Marini P, Schmid A, Jendrossek V, et al. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 2005;5:5.[CrossRef][Medline]
  7. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305–8.[Abstract/Free Full Text]
  8. Strasser A, O'Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem 2000;69:217–45.[CrossRef][Medline]
  9. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17:1675–87.[CrossRef][Medline]
  10. Yin XM, Wang K, Gross A, et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999;400:886–91.[CrossRef][Medline]
  11. Martinou JC, Green DR. Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2001;2:63–7.[CrossRef][Medline]
  12. Tschopp J, Irmler M, Thome M. Inhibition of fas death signals by FLIPs. Curr Opin Immunol 1998;10:552–8.[CrossRef][Medline]
  13. Kataoka T, Budd RC, Holler N, et al. The caspase-8 inhibitor FLIP promotes activation of NF-{kappa}B and Erk signaling pathways. Curr Biol 2000;10:640–8.[CrossRef][Medline]
  14. Krueger A, Baumann S, Krammer PH, Kirchhoff S. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001;21:8247–54.[Free Full Text]
  15. Golks A, Brenner D, Krammer PH, Lavrik IN. The c-FLIP-NH2 terminus (p22-FLIP) induces NF-{kappa}B activation. J Exp Med 2006;203:1295–305.[Abstract/Free Full Text]
  16. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-{kappa}B signals induce the expression of c-FLIP. Mol Cell Biol 2001;21:5299–305.[Abstract/Free Full Text]
  17. Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 2004;64:7086–91.[Abstract/Free Full Text]
  18. Jonsson G, Paulie S, Grandien A. High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells. Anticancer Res 2003;23:1213–8.[Medline]
  19. Flahaut M, Muhlethaler-Mottet A, Auderset K, et al. Persistent inhibition of FLIP(L) expression by lentiviral small hairpin RNA delivery restores death-receptor-induced apoptosis in neuroblastoma cells. Apoptosis 2006;11:255–63.[CrossRef][Medline]
  20. MacFarlane M, Harper N, Snowden RT, et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 2002;21:6809–18.[CrossRef][Medline]
  21. Van Geelen CM, de Vries EG, de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat 2004;7:345–58.[CrossRef][Medline]
  22. Tafuku S, Matsuda T, Kawakami H, Tomita M, Yagita H, Mori N. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma. Eur J Haematol 2006;76:64–74.[CrossRef][Medline]
  23. Malhi H, Gores GJ. TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene 2006;25:7333–5.[CrossRef][Medline]
  24. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228–37.[CrossRef][Medline]
  25. Schultze K, Bock B, Eckert A, et al. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis 2006;11:1503–12.[CrossRef][Medline]
  26. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004;11:915–23.[CrossRef][Medline]
  27. Panner A, James CD, Berger MS, Pieper RO. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 2005;25:8809–23.[Abstract/Free Full Text]
  28. Garofalo M, Romano G, Quintavalle C, et al. Selective inhibition of PED protein expression sensitizes B-cell chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis. Int J Cancer 2007;120:1215–22.[CrossRef][Medline]
  29. Ahn KS, Sethi G, Aggarwal BB. Simvastatin potentiates TNF-{alpha}-induced apoptosis through the down-regulation of NF-{kappa}B-dependent antiapoptotic gene products: role of I{kappa}B{alpha} kinase and TGF-β-activated kinase-1. J Immunol 2007;178:2507–16.[Abstract/Free Full Text]
  30. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002;3:401–10.[CrossRef][Medline]
  31. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997;16:6914–25.[CrossRef][Medline]
  32. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071–4.[Abstract/Free Full Text]
  33. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997;388:300–4.[CrossRef][Medline]
  34. Cummins JM, Kohli M, Rago C, Kinzler KW, Vogelstein B, Bunz F. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 2004;64:3006–8.[Abstract/Free Full Text]
  35. Vogler M, Durr K, Jovanovic M, Debatin KM, Fulda S. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 2007;26:248–57.[CrossRef][Medline]
  36. Zobel K, Wang L, Varfolomeev E, et al. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem Biol 2006;1:525–33. Erratum in: ACS Chem Biol 2006;1:601.[CrossRef][Medline]
  37. Schimmer AD, Welsh K, Pinilla C, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004;5:25–35.[CrossRef][Medline]
  38. Hao JH, Yu M, Liu FT, Newland AC, Jia L. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Cancer Res 2004;64:3607–16.[Abstract/Free Full Text]
  39. Ray S, Bucur O, Almasan A. Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis 2005;10:1411–8.[CrossRef][Medline]
  40. Song JJ, An JY, Kwon YT, Lee YJ. Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL. J Biol Chem 2007;282:319–28.[Abstract/Free Full Text]
  41. Clohessy JG, Zhuang J, de Boer J, Gil-Gomez G, Brady HJ. Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J Biol Chem 2006;281:5750–9.[Abstract/Free Full Text]
  42. Taniai M, Grambihler A, Higuchi H, et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004;64:3517–24.[Abstract/Free Full Text]
  43. Trauzold A, Siegmund D, Schniewind B, et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006;25:7434–9.[CrossRef][Medline]
  44. Oltersdorf T, Elmore SW, Shoemaker AR, et al. Inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677–81.[CrossRef][Medline]
  45. Ishimura N, Isomoto H, Bronk SF, Gores GJ. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 2006;290:G129–36.[Abstract/Free Full Text]
  46. Cunningham SJ. Cloning and characterization of a novel cDNA isolated from human β cells. Doctoral thesis, The University of Texas Medical Branch, Graduate School of Biomedical Sciences at Galveston; 1996.
  47. Chow VT, Lee SS. DENN, a novel human gene differentially expressed in normal and neoplastic cells. DNA Seq 1996;6:263–73.[Medline]
  48. Schievella AR, Chen JH, Graham JR, Lin LL. MADD, a novel death domain protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated protein kinase. J Biol Chem 1997;272:12069–75.[Abstract/Free Full Text]
  49. Chow VT, Lim KM, Lim D. The human DENN gene: genomic organization, alternative splicing, and localization to chromosome 11p11.21-p11.22. Genome 1998;41:543–52.[Medline]
  50. Al-Zoubi AM, Efimova EV, Kaithamana S, et al. Contrasting effects of IG20 and its splice isoforms, MADD and DENN-SV, on tumor necrosis factor {alpha}-induced apoptosis and activation of caspase-8 and -3. J Biol Chem 2001;276:47202–11.[Abstract/Free Full Text]
  51. Murakami-Mori K, Mori S, Bonavida B, Nakamura S. Implication of TNF receptor-I-mediated extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation in growth of AIDS-associated Kaposi's sarcoma cells: a possible role of a novel death domain protein MADD in TNF-{alpha}-induced ERK1/2 activation in Kaposi's sarcoma cells. J Immunol 1999;162:3672.[Abstract/Free Full Text]
  52. Efimova EV, Al-Zoubi AM, Martinez O, et al. IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs. Oncogene 2004;23:1076–87.[CrossRef][Medline]
  53. Ramaswamy M, Efimova EV, Martinez O, Mulherkar NU, Singh SP, Prabhakar BS. IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC. Oncogene 2004;23:6083–94.[CrossRef][Medline]
  54. Efimova EV, Martinez O, Lokshin A, Arima T, Prabhakar BS. IG20, a MADD splice variant, increases cell susceptibility to {gamma}-irradiation and induces soluble mediators that suppress tumor cell growth. Cancer Res 2003;63:8768–76.[Abstract/Free Full Text]
  55. Lim KM, Chow VT. Induction of marked apoptosis in mammalian cancer cell lines by antisense DNA treatment to abolish expression of DENN (differentially expressed in normal and neoplastic cells). Mol Carcinog 2002;35:110–6.[CrossRef][Medline]
  56. Lim KM, Yeo WS, Chow VT. Antisense abrogation of DENN expression induces apoptosis of leukemia cells in vitro, causes tumor regression in vivo and alters the transcription of genes involved in apoptosis and the cell cycle. Int J Cancer 2004;109:24–57.[CrossRef][Medline]
  57. Del Villar K, Miller CA. Down-regulation of DENN/MADD, a TNF receptor binding protein, correlates with neuronal cell death in Alzheimer's disease brain and hippocampal neurons. Proc Natl Acad Sci U S A 2004;101:4210–5.[Abstract/Free Full Text]
  58. Mulherkar N, Ramaswamy M, Mordi DC, Prabhakar BS. MADD/DENN splice variant of the IG20 gene is necessary and sufficient for cancer cell survival. Oncogene 2006;25:6252–61.[CrossRef][Medline]
  59. Mulherkar N, Prasad KV, Prabhakar BS. MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation: Knock-down enhances TRAIL-induced apoptosis of cancer cells. J Biol Chem 2007;11715–21.
  60. Kim HS, Lee JW, Soung YH, et al. Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology 2003;125:708–15.[CrossRef][Medline]
  61. Leverkus M, Sprick MR, Wachter T, et al. TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: differential contribution of TRAIL receptors 1 and 2. J Invest Dermatol 2003;121:149–55.[CrossRef][Medline]
  62. Liu X, Yue P, Khuri FR, Sun SY. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 2004;64:5078–83.[Abstract/Free Full Text]
  63. Teitz T, Lahti JM, Kidd VJ. Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death. J Mol Med 2001;79:428–36.[CrossRef][Medline]
  64. Ruiz de Almodovar C, Ruiz-Ruiz C, Rodriguez A, Ortiz-Ferron G, Redondo JM, Lopez-Rivas A. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site. J Biol Chem 2004;279:4093–101.[Abstract/Free Full Text]
  65. Wu GS, Burns TF, McDonald ER III, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141–3.[CrossRef][Medline]
  66. Riccioni R, Pasquini L, Mariani G, et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 2005;90:612–24.[Abstract/Free Full Text]
  67. Hopkins-Donaldson S, Ziegler A, Kurtz S, et al. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 2003;10:356–64.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
M. Subramanian, T. Pilli, P. Bhattacharya, F. Pacini, Y. E. Nikiforov, P. V. Kanteti, and B. S. Prabhakar
Knockdown of IG20 Gene Expression Renders Thyroid Cancer Cells Susceptible to Apoptosis
J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1467 - 1471.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. C. Li, J. R. Sheng, N. Mulherkar, B. S. Prabhakar, and M. N. Meriggioli
Regulation of Apoptosis and Caspase-8 Expression in Neuroblastoma Cells by Isoforms of the IG20 Gene
Cancer Res., September 15, 2008; 68(18): 7352 - 7361.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prabhakar, B. S.
Right arrow Articles by Prasad, K. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prabhakar, B. S.
Right arrow Articles by Prasad, K. V.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online